


Status: Currently Official on 15-Feb-2025
 Official Date: Official as of 01-May-2020
 Document Type: NF Monographs
 DocId: GUID-205AE5DA-ED0F-4031-A0B4-4271A13DE74E_4_en-US
 DOI: https://doi.org/10.31003/USPNF_M907_04_01
 DOI Ref: xh0vh

© 2025 USPC
 Do not distribute

Methylpyrrolidone



C₅H₉NO 99.1

1-Methyl-2-pyrrolidinone;
 N-Methyl-2-pyrrolidone;
 N-Methylpyrrolidone;
 1-Methyl-2-pyrrolidone;
 Pyrrolidin, 1-methyl-2-one-;
 1-Methylpyrrolidin-2-one;
 N-Methyl-γ-butyrolactam;
 N-Methyl tetrahydropyrrolone;
 1-Methyl-2-oxopyrrolidine;
 N-Methyl-1-oxotetramethyleneamine;
 2-Methyl-2-azacyclopentanone CAS RN®: 872-50-4.

IDENTIFICATION

Change to read:

- A. ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197F](#) ▲ (CN 1-MAY-2020)

IMPURITIES

• ORGANIC IMPURITIES

Standard solution: To 1 mL of [USP Methylpyrrolidone RS](#), add 1 mL of pyrrolidone, and dilute with methylene chloride to 20 mL.

Sample solution: Methylpyrrolidone (neat)

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: GC

Detector: Flame ionization

Column: 0.32-mm × 30-m fused-silica capillary; 5-μm layer of phase G2

Temperatures

Injector: 280°

Detector: 280°

Column: See [Table 1](#).

Table 1

Initial Temperature (°)	Temperature Ramp (°/min)	Final Temperature (°)	Hold Time at Final Temperature (min)
100	—	100	0
100	3	170	30

Carrier gas: Nitrogen

Linear velocity: 20 cm/s

Injection type: Split ratio about 100:1

Injection volume: 1 μL

System suitability

Sample: Standard solution

Suitability requirements**Resolution:** NLT 2.0 between pyrrolidone and methylpyrrolidone**Analysis****Samples:** Standard solution and Sample solution

Calculate the percentage of each impurity, excluding any solvent peaks and peaks NMT 0.02%, in the portion of Methylpyrrolidone taken:

$$\text{Result} = (r_u/r_T) \times 100$$

r_u = peak response of each individual impurity from the *Sample solution*

r_T = sum of the responses of all the peaks from the *Sample solution*

Acceptance criteria: NMT 0.1% of any individual impurity; and NMT 0.3% of total impurities**SPECIFIC TESTS**• **ALKALINITY****Bromothymol blue solution:** Dissolve 50 mg of bromothymol blue in a mixture of 4 mL of 0.02 M sodium hydroxide and 20 mL of alcohol, and dilute with water to 100 mL.**Sample:** Methylpyrrolidone (neat)**Analysis:** Add 0.5 mL of *Bromothymol blue solution* as indicator to 50 mL of water, and adjust with 0.02 M potassium hydroxide or 0.02 M hydrochloric acid until a yellow color is obtained. Add 50 mL of the *Sample*. Titrate with 0.02 M hydrochloric acid to the initial coloration.**Acceptance criteria:** NMT 8.0 mL of 0.02 M hydrochloric acid is required.**Change to read:**• **CLARITY OF SOLUTION**[NOTE—The *Sample* is to be compared to the *Reference suspension* in diffused daylight 5 min after preparation of the *Reference suspension*.]**Hydrazine solution:** 10 mg/mL of hydrazine sulfate. [NOTE—Allow to stand 4–6 h before use.]**Methenamine solution:** Transfer 2.5 g of methenamine to a 100-mL glass-stoppered flask, add 25.0 mL of water, insert the glass stopper, and mix to dissolve.**Primary opalescent suspension**

[NOTE—This suspension is stable for 2 months, provided it is stored in a glass container free from surface defects. The suspension must not adhere to the glass and must be well mixed before use.]

Transfer 25.0 mL of the *Hydrazine solution* to the *Methenamine solution* in the 100-mL glass-stoppered flask. [NOTE—Allow to stand for 24 h.]**Opalescence standard:** Transfer 15.0 mL of the *Primary opalescent suspension* to a 1000-mL volumetric flask, and dilute with water to volume. [NOTE—This suspension should not be used beyond 24 h after preparation.]**Reference suspension:** Transfer 5.0 mL of the *Opalescence standard* to a 100-mL volumetric flask, and dilute with water to volume.**Sample:** Methylpyrrolidone (neat)**Analysis:** Transfer a sufficient portion of the *Sample* to a test tube of colorless, transparent, neutral glass with a flat base and an internal diameter of 15–25 mm to obtain a depth of 40 mm. Similarly transfer portions of the *Reference suspension* and water to separate matching test tubes. Compare the *Sample*, *Reference suspension*, and water in diffused daylight, viewing vertically against a black background (see ▲ [Visual Comparison \(630\)](#) ▲ (CN 1-May-2019)). [NOTE—The diffusion of light must be such that the *Reference suspension* can readily be distinguished from water.]**Acceptance criteria:** The *Sample* shows the same clarity as that of water, or its opalescence is not more pronounced than that of the *Reference suspension*.**Change to read:**• **COLOR OF SOLUTION****Comparison solution:** Mix 3.0 mL of ferric chloride CS, 3.0 mL of cobaltous chloride CS, and 2.4 mL of cupric sulfate CS with 0.3 N hydrochloric acid to make 10 mL. Dilute 1.0 mL of this solution with 0.3 N hydrochloric acid to make 100 mL. [NOTE—Prepare and use this solution immediately.]**Sample:** Methylpyrrolidone (neat)**Analysis:** Transfer a sufficient portion of the *Sample* to a test tube of colorless, transparent, neutral glass with a flat base and an internal diameter of 15–25 mm to obtain a depth of 40 mm. Similarly transfer a portion of the *Comparison solution* to a separate matching test tube. Compare the color of the *Sample* with that of the *Comparison solution* in diffused daylight, viewing vertically against a white background (see ▲ [Visual Comparison \(630\)](#) ▲ (CN 1-May-2019)).**Acceptance criteria:** The *Sample* is not more intensely colored than the *Comparison solution*.• **WATER DETERMINATION, Method Ic (921):** NMT 0.1%, determined on 1.0 g**ADDITIONAL REQUIREMENTS**• **PACKAGING AND STORAGE:** Preserve in light-resistant containers.• **USP REFERENCE STANDARDS (11):**[USP Methylpyrrolidone RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
METHYLPYRROLIDONE	Documentary Standards Support	SE2020 Simple Excipients

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 38(5)

Current DocID: GUID-205AE5DA-ED0F-4031-A0B4-4271A13DE74E_4_en-US

DOI: https://doi.org/10.31003/USPNF_M907_04_01

DOI ref: [xh0vh](#)

OFFICIAL